Karyopharm Therapeutics
KPTI
50 hedge funds and large institutions have $19M invested in Karyopharm Therapeutics in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 10 closing their positions.
1,166% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $127K
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
38% more capital invested
Capital invested by funds: $13.7M → $19M (+$5.28M)
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
8.03% more ownership
Funds ownership: 43.04% → 51.07% (+8%)
2% more funds holding
Funds holding: 49 → 50 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$2.89M |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$480K |
| 3 |
JP Morgan Chase
New York
|
+$420K |
| 4 |
SAM
Silverback Asset Management
Chapel Hill,
North Carolina
|
+$343K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$335K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$668K |
| 2 |
Millennium Management
New York
|
-$115K |
| 3 |
SC
Shay Capital
New York
|
-$95.1K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$88.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
51
Altium Capital Management
New York
| – | -$185K | -49,333 | Closed |
|
|
SC
52
Shay Capital
New York
| – | -$95.1K | -25,417 | Closed |
|
|
UOC
53
UBS O'Connor
Chicago,
Illinois
| – | -$88.4K | -23,640 | Closed |
|
|
54
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$56.7K | -11,548 | Closed |
|
55
Jane Street
New York
| – | -$42.7K | -11,420 | Closed |
|
|
LSA
56
Leonteq Securities AG
Zurich,
Switzerland
| – | -$37.3K | -10,000 | Closed |
|
|
CCM
57
Coldstream Capital Management
Bellevue,
Washington
| – | -$1.24K | -331 | Closed |
|
|
QC
58
Quent Capital
New York
| – | -$864 | -231 | Closed |
|
|
VWA
59
VSM Wealth Advisory
Hunt Valley,
Maryland
| – | -$497 | -133 | Closed |
|
|
DB
60
Danske Bank
Copenhagen K,
Denmark
| – | -$11 | -3 | Closed |
|
KPTI Hedge Fund Activity: Q2 2025 in Review
50 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2025, worth a combined $19M — up 38% from $13.7M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new KPTI positions and 10 closed out — a net gain of 1 holder — while 12 added to existing stakes and 7 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $2.89M. The largest seller was Palo Alto Investors, cutting an estimated $668K.
- 50 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2025, up from 49 in Q1 2025.
- Funds reported $19M of Karyopharm Therapeutics stock for Q2 2025, up 38% quarter-over-quarter.
- 11 funds opened new Karyopharm Therapeutics positions in Q2 2025 and 10 closed out, a net change of +1 holder.
- The largest Karyopharm Therapeutics buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $2.89M added.
- The largest Karyopharm Therapeutics seller in Q2 2025 was Palo Alto Investors, an estimated $668K sold.
Based on aggregated 13F filings for Q2 2025.